Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
Cars are becoming completely unaffordable in US, tariffs will hammer lower-income car shoppers : Nissan
16/04/2025
Short-term volatility may persist, but financials still the go-to sector : Rohit Srivastava
16/04/2025
9 tactics Anmol Singh Jaggi used to siphon money from Gensol
16/04/2025
Dipan Mehta urges caution and focus on fundamentals as uncertainty persists
16/04/2025
China changes top trade negotiator amid tariff war with US
16/04/2025
IGL, MGL shares tumble up to 7% after changes in domestic gas allocations
16/04/2025
